Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW) Drops By 74.5%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW) was the recipient of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 4,007 shares, a decline of 74.5% from the January 15th total of 15,707 shares. Based on an average daily volume of 16,755 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 16,755 shares, the short-interest ratio is presently 0.2 days.

Coeptis Therapeutics Stock Down 12.9%

COEPW traded down $0.00 on Wednesday, reaching $0.01. The stock had a trading volume of 3,912 shares, compared to its average volume of 20,519. The business’s 50-day moving average price is $0.01 and its two-hundred day moving average price is $0.02. Coeptis Therapeutics has a 12-month low of $0.00 and a 12-month high of $0.05.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics is a clinical‐stage biopharmaceutical company focused on developing novel therapies for neurodegenerative and neuroinflammatory disorders. The company’s proprietary platform is based on engineered analogs of small heat shock proteins designed to modulate cellular stress responses, reduce inflammation and protect neurons from degeneration. Coeptis’s lead program is being advanced in amyotrophic lateral sclerosis (ALS), with additional preclinical studies underway in conditions such as multiple sclerosis and other central nervous system diseases.

Using its heat shock protein analog technology, Coeptis seeks to address the underlying pathology of neurodegeneration rather than merely managing symptoms.